EA201891315A1 - Твердые дисперсии, содержащие стимулятор sgc - Google Patents
Твердые дисперсии, содержащие стимулятор sgcInfo
- Publication number
- EA201891315A1 EA201891315A1 EA201891315A EA201891315A EA201891315A1 EA 201891315 A1 EA201891315 A1 EA 201891315A1 EA 201891315 A EA201891315 A EA 201891315A EA 201891315 A EA201891315 A EA 201891315A EA 201891315 A1 EA201891315 A1 EA 201891315A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- solid dispersions
- dispersions containing
- sgc stimulator
- containing sgc
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260910P | 2015-11-30 | 2015-11-30 | |
| US201662359440P | 2016-07-07 | 2016-07-07 | |
| PCT/US2016/063312 WO2017095697A1 (en) | 2015-11-30 | 2016-11-22 | Solid dispersions comprising a sgc stimulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201891315A1 true EA201891315A1 (ru) | 2018-12-28 |
Family
ID=57590822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891315A EA201891315A1 (ru) | 2015-11-30 | 2016-11-22 | Твердые дисперсии, содержащие стимулятор sgc |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20190269619A1 (https=) |
| EP (1) | EP3383372B1 (https=) |
| JP (3) | JP6952707B2 (https=) |
| KR (1) | KR102841419B1 (https=) |
| CN (4) | CN116637076A (https=) |
| AU (1) | AU2016364976B2 (https=) |
| BR (1) | BR112018011154B1 (https=) |
| CA (1) | CA3006746C (https=) |
| EA (1) | EA201891315A1 (https=) |
| IL (2) | IL259493B (https=) |
| MX (3) | MX389961B (https=) |
| WO (1) | WO2017095697A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018015718A2 (pt) | 2016-02-01 | 2019-01-08 | Ironwood Pharmaceuticals Inc | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) |
| CN109563077B (zh) | 2016-07-07 | 2026-03-10 | 赛克里翁治疗有限公司 | 用于制备可溶性鸟苷酸环化酶刺激剂的新方法 |
| WO2018009602A2 (en) * | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
| WO2019055859A1 (en) | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| MA71753A (fr) * | 2018-01-10 | 2025-05-30 | Cyclerion Therapeutics, Inc. | Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| WO2019172420A1 (ja) * | 2018-03-09 | 2019-09-12 | 協和発酵キリン株式会社 | 医薬組成物 |
| EP3829644A4 (en) * | 2018-07-30 | 2022-05-04 | Ricoh Company, Ltd. | PROCESS FOR MANUFACTURING PARTICLES AND PARTICLE AND MEDICATION MANUFACTURED BY THE PROCESS |
| JP7503781B2 (ja) * | 2018-07-30 | 2024-06-21 | 株式会社リコー | 粒子の製造方法、並びに、それにより製造された粒子及び医薬 |
| CA3149182A1 (en) * | 2019-09-23 | 2021-04-01 | Bionomics Limited | Therapeutic formulations and uses thereof |
| WO2021086967A1 (en) | 2019-10-29 | 2021-05-06 | Cyclerion Therapeutics, Inc. | Treatment of diabetic nephropathy with an sgc stimulator |
| US20240000769A1 (en) * | 2020-12-18 | 2024-01-04 | UCB Biopharma SRL | Amorphous solid dispersions |
| US20240366596A1 (en) | 2021-07-28 | 2024-11-07 | Cyclerion Therapeutics, Inc. | Treatment of hfpef in post-menopausal women with an sgc stimulator |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| EP1027886B1 (en) * | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
| EP2654726A1 (en) * | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| US9309235B2 (en) * | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| SI2970243T1 (sl) * | 2013-03-15 | 2020-04-30 | Cyclerion Therapeutics, Inc. | SGC stimulatorji |
| WO2015106268A1 (en) * | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
-
2016
- 2016-11-22 CA CA3006746A patent/CA3006746C/en active Active
- 2016-11-22 KR KR1020187018204A patent/KR102841419B1/ko active Active
- 2016-11-22 EA EA201891315A patent/EA201891315A1/ru unknown
- 2016-11-22 AU AU2016364976A patent/AU2016364976B2/en active Active
- 2016-11-22 WO PCT/US2016/063312 patent/WO2017095697A1/en not_active Ceased
- 2016-11-22 CN CN202310714716.7A patent/CN116637076A/zh active Pending
- 2016-11-22 CN CN202310714714.8A patent/CN116942616A/zh active Pending
- 2016-11-22 US US15/780,212 patent/US20190269619A1/en not_active Abandoned
- 2016-11-22 CN CN202310714725.6A patent/CN116637077A/zh active Pending
- 2016-11-22 JP JP2018547255A patent/JP6952707B2/ja active Active
- 2016-11-22 CN CN201680077389.7A patent/CN108883071A/zh active Pending
- 2016-11-22 EP EP16816486.1A patent/EP3383372B1/en active Active
- 2016-11-22 BR BR112018011154-6A patent/BR112018011154B1/pt active IP Right Grant
- 2016-11-22 MX MX2018006422A patent/MX389961B/es unknown
-
2018
- 2018-05-21 IL IL259493A patent/IL259493B/en unknown
- 2018-05-24 MX MX2022001656A patent/MX2022001656A/es unknown
- 2018-05-24 MX MX2022001655A patent/MX2022001655A/es unknown
-
2021
- 2021-09-28 JP JP2021157646A patent/JP7277534B2/ja active Active
-
2022
- 2022-02-03 IL IL290338A patent/IL290338B2/en unknown
-
2023
- 2023-05-08 JP JP2023076655A patent/JP7641320B2/ja active Active
- 2023-12-29 US US18/400,392 patent/US20240293324A1/en not_active Abandoned
-
2024
- 2024-05-16 US US18/665,775 patent/US20250017862A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,072 patent/US20250255821A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891315A1 (ru) | Твердые дисперсии, содержащие стимулятор sgc | |
| EA202091324A1 (ru) | Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином | |
| PH12019501937A1 (en) | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | |
| JOP20200122B1 (ar) | مركبات مفيدة لتثبيط cdk7 | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA202091262A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| PH12018500284B1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| MX2017008520A (es) | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201890001A1 (ru) | Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk) | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| MA40219B1 (fr) | Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| EA201892415A1 (ru) | Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида | |
| CY1124397T1 (el) | Κρυσταλλικο (2s,4r)-5-(5'-χλωρο-2-φθορο-[1,1'-διφαινυλ] -4-υλ)-2-(αιθοξυμεθυλ)-4-(3-υδροξυϊσοξαζολη-5- καρβοξαμιδο) -2-μεθυλπεντανοϊκο οξυ και χρησεις αυτου | |
| EA201991045A1 (ru) | Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора | |
| MX381323B (es) | Derivado de imidazopirimidina e imidazotriazina, y composición farmacéutica que lo comprende. | |
| MX387920B (es) | Peptidos antagonistas de prgc. | |
| EA202090397A1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора | |
| EA201891739A1 (ru) | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH) | |
| EA201991746A1 (ru) | Производные пиразола в качестве ингибиторов бромодомена | |
| PE20170200A1 (es) | Composicion farmaceutica que combina un anticonvulsivante y un derivado del acido nicotinico |